Practical recommendations from the STREAM clinical trial
STREAM is a multi-country clinical trial evaluating shorter, more tolerable regimens for multidrug-resistant tuberculosis (MDR-TB). The trial offered an exceptional opportunity to evaluate key issues related to Implementing Clinical Trials, Community Engagement, and Pharmacy and Clinical Supplies. This site offers practical recommendations drawn from the lessons learned over the course of the trial.
- Implementing Clinical Trials View →
- Community Engagement View →
- Pharmacy and Clinical Supplies View →
This site is made possible by the generous support of the American people through the USAID TREAT TB Cooperative Agreement No. GHN-A-00-08-00004. This site was developed by Vital Strategies (trial sponsor), with input from key partners including the Medical Research Council Clinical Trials Unit at University College London (MRC CTU at UCL), Liverpool School of Tropical Medicine, REDE-TB, Wits Health Consortium, STREAM trial sites and STREAM CABs.
STREAM was conceived by The Union and key partners, including Vital Strategies, the MRC CTU at UCL (main implementing partner), the Institute of Tropical Medicine (microbiology lead) and Liverpool School of Tropical Medicine (health economics lead). STREAM Stage 1 was funded by The United States Agency for International Development (USAID), with additional support from the United Kingdom Medical Research Council (MRC) and the United Kingdom Department for International Development (DFID) under the MRC/DFID Concordat agreement. STREAM Stage 2 is being funded by USAID and Janssen Pharmaceuticals, the maker of bedaquiline, with additional support from MRC and DFID.